New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 26, 2026) - Kahn Swick & Foti, LLC ("KSF")...

NEW YORK, NY - August 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than September 28, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. The complaint alleges that on July 27, 2026, before the market o…

/PRNewswire/ -- National investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR). Following...

Capricor Therapeutics Inc. jumped as stocks have been trading up by 10.37 percent following highly positive clinical trial news Key Takeaways Traders Need To Know Cantor hiked its CAPR rating to Overweight and lifted its price target to $28 from $3.50 after Q2 earnings and fresh FDA engagement on

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) that a class action lawsuit has been filed on behalf of...